IRIS/Inhalation RfCs
From Opasnet
| Moderator:Erika (see all) |
|
|
| Upload data
|
Question
What are the Inhalation RfCs according to the IRIS database?
Answer
| Obs | Substance | CASRN | Critical Effact(s) | Unit | Inhalation RfC | Type of RfC | Point of Departure(s)* | Overall Confidence | IRIS identifier |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Acenaphthene | 83-32-9 | Not Assessed under the IRIS program. | ||||||
| 2 | Acenaphthylene | 208-96-8 | Not Assessed under the IRIS program. | ||||||
| 3 | Acephate | 30560-19-1 | Not Assessed under the IRIS program. | ||||||
| 4 | Acetaldehyde | 75-07-0 | Degeneration of olfactory epithelium | mg /m3 | 9x10-3 | NOAEL (HEC) | 8.7 | Low | 0290 |
| 5 | Acetochlor | 34256-82-1 | Not Assessed under the IRIS program. | ||||||
| 6 | Acetone | 67-64-1 | Not Assessed under the IRIS program. | ||||||
| 7 | Acetonitrile | 75-05-8 | Not Assessed under the IRIS program. | ||||||
| 8 | Acetophenone | 98-86-2 | Mortality | mg /m3 | 6x10-2 | NOAEL (HEC) | 60 | Medium | 0205 |
| 9 | Acetyl chloride | 75-36-5 | Not Assessed under the IRIS program. | ||||||
| 10 | Acifluorfen, sodium | 62476-59-9 | Not Assessed under the IRIS program. | ||||||
| 11 | Acrolein | 107-02-8 | Nasal lesions | mg /m3 | 2x10-5 | LOAEL (HEC) | 0.02 | Medium | 0364 |
| 12 | Acrylamide | 79-06-1 | Degenerative nerve changes | mg /m3 | 0.006 | HEC (BMDL) | 0.18 | Medium | 0286 |
| 13 | Acrylic acid | 79-10-7 | Degeneration of the nasal olfactory epithelium | mg /m3 | 1x10-3 | LOAEL (HEC) | 0.33 | Medium | 0002 |
| 14 | Acrylonitrile | 107-13-1 | Degeneration and inflammation of nasal respiratory epithelium; hyperplasia of mucous secreting cells | mg /m3 | 2x10-3 | LOAEL (HEC) | 1.9 | Medium | 0206 |
| 15 | Adiponitrile | 111-69-3 | Not Assessed under the IRIS program. | ||||||
| 16 | Alachlor | 15972-60-8 | Not Assessed under the IRIS program. | ||||||
| 17 | Alar | 1596-84-5 | Not Assessed under the IRIS program. | ||||||
| 18 | Aldicarb | 116-06-3 | Not Assessed under the IRIS program. | ||||||
| 19 | Aldicarb sulfone | 1646-88-4 | Not Assessed under the IRIS program. | ||||||
| 20 | Aldrin | 309-00-2 | Not Assessed under the IRIS program. | ||||||
| 21 | Ally | 74223-64-6 | Not Assessed under the IRIS program. | ||||||
| 22 | Allyl alcohol | 107-18-6 | Not Assessed under the IRIS program. | ||||||
| 23 | Allyl chloride | 107-05-1 | Functional and histological peripheral neurotoxicity | mg /m3 | 1x10-3 | NOAEL (HEC) | 3.6 | Low | 0387 |
| 24 | Aluminum phosphide | 20859-73-8 | Not Assessed under the IRIS program. | ||||||
| 25 | Amdro | 67485-29-4 | Not Assessed under the IRIS program. | ||||||
| 26 | Ametryn | 834-12-8 | Not Assessed under the IRIS program. | ||||||
| 27 | 4-Aminopyridine | 504-24-5 | Not Assessed under the IRIS program. | ||||||
| 28 | Amitraz | 33089-61-1 | Not Assessed under the IRIS program. | ||||||
| 29 | Ammonia | 7664-41-7 | Not Assessed under the IRIS program. | ||||||
| 30 | Ammonium acetate | 631-61-8 | Not Assessed under the IRIS program. | ||||||
| 31 | Ammonium methacrylate | 16325-47-6 | Not Assessed under the IRIS program. | ||||||
| 32 | Ammonium sulfamate | 7773-06-0 | Not Assessed under the IRIS program. | ||||||
| 33 | Aniline | 62-53-3 | Lack of toxicity (other effect: Mild spleen toxicity ) | mg /m3 | 1x10-3 | NOAEL (HEC) | 3.4 | Low | 0350 |
| 34 | ortho-Anisidine | 90-04-0 | Information reviewed but value not estimated. Refer to IRIS Summary. | 0610 | |||||
| 35 | Anthracene | 120-12-7 | Not Assessed under the IRIS program. | ||||||
| 36 | Antimony | 7440-36-0 | Not Assessed under the IRIS program. | ||||||
| 37 | Antimony trioxide | 1309-64-4 | Pulmonary toxicity, chronic interstitial inflammation | mg /m3 | 2x10-4 | BMC10 (HEC) | 0.074 | Medium | 0676 |
| 38 | Apollo | 74115-24-5 | Not Assessed under the IRIS program. | ||||||
| 39 | Aramite | 140-57-8 | Not Assessed under the IRIS program. | ||||||
| 40 | Aroclor 1016 | 12674-11-2 | Not Assessed under the IRIS program. | ||||||
| 41 | Aroclor 1248 | 12672-29-6 | Not Assessed under the IRIS program. | ||||||
| 42 | Aroclor 1254 | 11097-69-1 | Not Assessed under the IRIS program. | ||||||
| 43 | Arsenic, inorganic | 7440-38-2 | Not Assessed under the IRIS program. | ||||||
| 44 | Arsine | 7784-42-1 | Increased hemolysis, abnormal RBC morphology, and increased spleen weight (other effect: Increased hemolysis, increased spleen weight, and impaired compensatory erythropoiesis) | mg /m3 | 5x10-5 | NOAEL (HEC) | 0.014 | Medium | 0672 |
| 45 | Asbestos | 1332-21-4 | Not Assessed under the IRIS program. | ||||||
| 46 | Assure | 76578-14-8 | Not Assessed under the IRIS program. | ||||||
| 47 | Asulam | 3337-71-1 | Not Assessed under the IRIS program. | ||||||
| 48 | Atrazine | 1912-24-9 | Not Assessed under the IRIS program. | ||||||
| 49 | Avermectin B1 | 65195-55-3 | Not Assessed under the IRIS program. | ||||||
| 50 | Azobenzene | 103-33-3 | Not Assessed under the IRIS program. | ||||||
| 51 | Barium and Compounds | 7440-39-3 | Not Assessed under the IRIS program. | ||||||
| 52 | Barium cyanide | 542-62-1 | Not Assessed under the IRIS program. | ||||||
| 53 | Baygon | 114-26-1 | Not Assessed under the IRIS program. | ||||||
| 54 | Bayleton | 43121-43-3 | Not Assessed under the IRIS program. | ||||||
| 55 | Baythroid | 68359-37-5 | Not Assessed under the IRIS program. | ||||||
| 56 | Benefin | 1861-40-1 | Not Assessed under the IRIS program. | ||||||
| 57 | Benomyl | 17804-35-2 | Not Assessed under the IRIS program. | ||||||
| 58 | Bentazon (Basagran) | 25057-89-0 | Not Assessed under the IRIS program. | ||||||
| 59 | Benz[a]anthracene | 56-55-3 | Not Assessed under the IRIS program. | ||||||
| 60 | Benzaldehyde | 100-52-7 | Not Assessed under the IRIS program. | ||||||
| 61 | Benzene | 71-43-2 | Decreased lymphocyte count | mg /m3 | 3x10-2 | BMCL | 8.2 | Medium | 0276 |
| 62 | Benzidine | 92-87-5 | Information reviewed but value not estimated. Refer to IRIS Summary. | 0135 | |||||
| 63 | Benzo[a]pyrene (BaP) | 50-32-8 | Not Assessed under the IRIS program. | ||||||
| 64 | Benzo[b]fluoranthene | 205-99-2 | Not Assessed under the IRIS program. | ||||||
| 65 | Benzo[g,h,i]perylene | 191-24-2 | Not Assessed under the IRIS program. | ||||||
| 66 | Benzo[k]fluoranthene | 207-08-9 | Not Assessed under the IRIS program. | ||||||
| 67 | Benzoic acid | 65-85-0 | Not Assessed under the IRIS program. | ||||||
| 68 | Benzotrichloride | 98-07-7 | Not Assessed under the IRIS program. | ||||||
| 69 | Benzyl chloride | 100-44-7 | Information reviewed but value not estimated. Refer to IRIS Summary. | 0393 | |||||
| 70 | Beryllium and compounds | 7440-41-7 | Beryllium sensitization and progression to CBD | mg /m3 | 2x10-5 | LOAEL (HEC) | 0.0002 | Medium | 0012 |
| 71 | Bidrin | 141-66-2 | Not Assessed under the IRIS program. | ||||||
| 72 | Biphenthrin | 82657-04-3 | Not Assessed under the IRIS program. | ||||||
| 73 | 1,1-Biphenyl | 92-52-4 | Information reviewed but value not estimated. Refer to IRIS Summary. | 0013 | |||||
| 74 | Bis(2-chloro-1-methylethyl) ether | 108-60-1 | Not Assessed under the IRIS program. | ||||||
| 75 | Bis(2-chloroethoxy)methane | 111-91-1 | Not Assessed under the IRIS program. | ||||||
| 76 | Bis(chloroethyl)ether (BCEE) | 111-44-4 | Information reviewed but value not estimated. Refer to IRIS Summary. | 0137 | |||||
| 77 | Bis(chloromethyl)ether (BCME) | 542-88-1 | Information reviewed but value not estimated. Refer to IRIS Summary. | 0375 | |||||
| 78 | Bisphenol A. | 80-05-7 | Not Assessed under the IRIS program. | ||||||
| 79 | Boron and Compounds | 7440-42-8 | Information reviewed but value not estimated. Refer to IRIS Summary. | 0410 | |||||
| 80 | Bromate | 15541-45-4 | Information reviewed but value not estimated. Refer to IRIS Summary. | 1002 | |||||
| 81 | Brominated dibenzofurans | NA | Not Assessed under the IRIS program. | ||||||
| 82 | Bromobenzene | 108-86-1 | Hepatocellular cytomegaly in female B6C3F1 mice | mg /m3 | 6x10-2 | BMCL10 (HEC) | 63 | Low/Medium | 1020 |
| 83 | Bromochloromethane | 74-97-5 | Not Assessed under the IRIS program. | ||||||
| 84 | Bromodichloromethane | 75-27-4 | Not Assessed under the IRIS program. | ||||||
| 85 | p-Bromodiphenyl ether | 101-55-3 | Not Assessed under the IRIS program. | ||||||
| 86 | Bromoform | 75-25-2 | Information reviewed but value not estimated. Refer to IRIS Summary. | 0214 | |||||
| 87 | Bromomethane | 74-83-9 | Degenerative and proliferative lesions of the olfactory epithelium of the nasal cavity | mg /m3 | 5x10-3 | LOAEL (HEC) | 0.48 | High | 0015 |
| 88 | Bromotrichloromethane | 75-62-7 | Not Assessed under the IRIS program. | ||||||
| 89 | Bromoxynil | 1689-84-5 | Not Assessed under the IRIS program. | ||||||
| 90 | Bromoxynil octanoate | 1689-99-2 | Not Assessed under the IRIS program. | ||||||
| 91 | 1,3-Butadiene | 106-99-0 | Ovarian atrophy | mg /m3 | 2x10-3 | BMCL10 (HEC) | 1.98 | Medium | 0139 |
| 92 | n-Butanol | 71-36-3 | Not Assessed under the IRIS program. | ||||||
| 93 | Butyl benzyl phthalate | 85-68-7 | Not Assessed under the IRIS program. | ||||||
| 94 | Butylate | 2008-41-5 | Not Assessed under the IRIS program. | ||||||
| 95 | t-Butylchloride | 507-20-0 | Not Assessed under the IRIS program. | ||||||
| 96 | Butylphthalyl butylglycolate (BPBG) | 85-70-1 | Not Assessed under the IRIS program. | ||||||
| 97 | Cacodylic acid | 75-60-5 | Not Assessed under the IRIS program. | ||||||
| 98 | Cadmium | 7440-43-9 | Not Assessed under the IRIS program. | ||||||
| 99 | Calcium cyanide | 592-01-8 | Not Assessed under the IRIS program. | ||||||
| 100 | Caprolactam | 105-60-2 | Information reviewed but value not estimated. Refer to IRIS Summary. | 0357 | |||||
| 101 | Captafol | 2425-06-1 | Not Assessed under the IRIS program. | ||||||
| 102 | Captan | 133-06-2 | Not Assessed under the IRIS program. | ||||||
| 103 | Carbaryl | 63-25-2 | Information reviewed but value not estimated. Refer to IRIS Summary. | 0019 | |||||
| 104 | Carbofuran | 1563-66-2 | Not Assessed under the IRIS program. | ||||||
| 105 | Carbon disulfide | 75-15-0 | Peripheral nervous system dysfunction | mg /m3 | 7x10-1 | BMC10 (HEC) | 19.7 | Medium | 0217 |
| 106 | Carbon tetrachloride | 56-23-5 | Fatty changes in the liver | mg /m3 | 0.1 | BMCL10 (HEC) | 14.3 | Medium | 0020 |
| 107 | Carbonyl sulfide | 463-58-1 | Information reviewed but value not estimated. Refer to IRIS Summary. | 0617 | |||||
| 108 | Carbosulfan | 55285-14-8 | Not Assessed under the IRIS program. | ||||||
| 109 | Carboxin | 5234-68-4 | Not Assessed under the IRIS program. | ||||||
| 110 | Cerium Oxide and Cerium Compounds | 1306-38-3 | Increased incidence of alveolar epithelial hyperplasia in the lungs of male and female rats | mg /m3 | 9x10-4 | BMCL (HEC) | 0.86 | Low | 1018 |
| 111 | Chloral hydrate | 302-17-0 | Not Assessed under the IRIS program. | ||||||
| 112 | Chloramben | 133-90-4 | Not Assessed under the IRIS program. | ||||||
| 113 | Chlordane (Technical) | 12789-03-6 | Hepatic effects | mg /m3 | 7x10-4 | NOAEL (HEC) | 0.65 | Low | 0142 |
| 114 | Chlordecone (Kepone) | 143-50-0 | Information reviewed but value not estimated. Refer to IRIS Summary. | 1017 | |||||
| 115 | Chlorimuron-ethyl | 90982-32-4 | Not Assessed under the IRIS program. | ||||||
| 116 | Chlorine | 7782-50-5 | Not Assessed under the IRIS program. | ||||||
| 117 | Chlorine cyanide | 506-77-4 | Not Assessed under the IRIS program. | ||||||
| 118 | Chlorine dioxide | 10049-04-4 | Vascular congestion and peribronchial edema (other effect: Hemorrhagic alveoli and congested capillaries in the lungs) | mg /m3 | 2x10-4 | LOAEL (HEC) | 0.64 | Low | 0496 |
| 119 | Chlorite (sodium salt) | 7758-19-2 | Information reviewed but value not estimated. Refer to IRIS Summary. | 0648 | |||||
| 120 | 1-Chloro-1,1-difluoroethane | 75-68-3 | No adverse effects | mg /m3 | 5x101 | NOAEL (HEC) | 14710 | Medium | 0661 |
| 121 | 2-Chloroacetophenone | 532-27-4 | Squamous hyperplasia of the nasal respiratory epithelium | mg /m3 | 3x10-5 | LOAEL (HEC) | 0.03 | Low | 0537 |
| 122 | p-Chloroaniline | 106-47-8 | Not Assessed under the IRIS program. | ||||||
| 123 | Chlorobenzene | 108-90-7 | Not Assessed under the IRIS program. | ||||||
| 124 | Chlorobenzilate | 510-15-6 | Not Assessed under the IRIS program. | ||||||
| 125 | 1-Chlorobutane | 109-69-3 | Not Assessed under the IRIS program. | ||||||
| 126 | 2-Chlorobutane | 78-86-4 | Not Assessed under the IRIS program. | ||||||
| 127 | Chlorocyclopentadiene | 41851-50-7 | Not Assessed under the IRIS program. | ||||||
| 128 | Chlorodifluoromethane | 75-45-6 | Increased kidney, adrenal and pituitary weights (other effect: Reduced maternal weight gain) | mg /m3 | 5x101 | NOAEL (HEC) | 5260 | Medium | 0657 |
| 129 | Chloroform | 67-66-3 | Not Assessed under the IRIS program. | ||||||
| 130 | Chloromethyl methyl ether (CMME) | 107-30-2 | Not Assessed under the IRIS program. | ||||||
| 131 | beta-Chloronaphthalene | 91-58-7 | Not Assessed under the IRIS program. | ||||||
| 132 | 2-Chlorophenol | 95-57-8 | Not Assessed under the IRIS program. | ||||||
| 133 | p-Chlorophenyl methyl sulfide | 123-09-1 | Not Assessed under the IRIS program. | ||||||
| 134 | p-Chlorophenyl methyl sulfone | 98-57-7 | Not Assessed under the IRIS program. | ||||||
| 135 | p-Chlorophenyl methyl sulfoxide | 934-73-6 | Not Assessed under the IRIS program. | ||||||
| 136 | Chloroprene | 126-99-8 | Increase in incidence of olfactory atrophy, alveolar hyperplasia, and splenic hematopoietic proliferation in male F344/N rats, female F344/N rats, and female B6C3F1 mice, respectively | mg /m3 | 2x10-2 | BMDL (HEC) | 2 | Medium/High | 1021 |
| 137 | Chlorothalonil | 1897-45-6 | Not Assessed under the IRIS program. | ||||||
| 138 | o-Chlorotoluene | 95-49-8 | Not Assessed under the IRIS program. | ||||||
| 139 | Chlorpropham | 101-21-3 | Not Assessed under the IRIS program. | ||||||
| 140 | Chlorpyrifos | 2921-88-2 | Not Assessed under the IRIS program. | ||||||
| 141 | Chlorsulfuron | 64902-72-3 | Not Assessed under the IRIS program. | ||||||
| 142 | Chromium(III), insoluble salts | 16065-83-1 | Information reviewed but value not estimated. Refer to IRIS Summary. | 0028 | |||||
| 143 | Chromium(VI) (Chromic acid mists and dissolved Cr(VI) aerosols) | 18540-29-9 | Nasal septum atrophy | mg /m3 | 8x10-6 | LOAEL (ADJ) | 0.000714 | Low | 0144 |
| 144 | Chromium(VI) (Cr(VI) particulates) | 18540-29-9 | Lactate dehydrogenase in bronchioalveolar lavage fluid | 1x10-4 | BMC10 (ADJ) | 0.034 | Medium | 0144 | |
| 145 | Chrysene | 218-01-9 | Not Assessed under the IRIS program. | ||||||
| 146 | Coke oven emissions | 8007-45-2 | Not Assessed under the IRIS program. | ||||||
| 147 | Copper | 7440-50-8 | Not Assessed under the IRIS program. | ||||||
| 148 | Copper cyanide | 544-92-3 | Not Assessed under the IRIS program. | ||||||
| 149 | Creosote | 8001-58-9 | Not Assessed under the IRIS program. | ||||||
| 150 | Crotonaldehyde | 123-73-9 | Not Assessed under the IRIS program. | ||||||
| 151 | Cumene | 98-82-8 | Increased kidney weights in female rats and adrenal weights in male and female rats | mg /m3 | 4x10-1 | NOAEL (HEC) | 435 | Medium | 0306 |
| 152 | Cyanazine | 21725-46-2 | Not Assessed under the IRIS program. | ||||||
| 153 | Cyanide, free | 57-12-5 | Not Assessed under the IRIS program. | ||||||
| 154 | Cyanogen | 460-19-5 | Not Assessed under the IRIS program. | ||||||
| 155 | Cyanogen bromide | 506-68-3 | Not Assessed under the IRIS program. | ||||||
| 156 | Cyclohexane | 110-82-7 | Reduced pup weights in the F1 and F2 generations | mg /m3 | 6 | BMCL1sd (HEC) | 1822 | Low/Medium | 1005 |
| 157 | Cyclohexanone | 108-94-1 | Not Assessed under the IRIS program. | ||||||
| 158 | Cyclohexylamine | 108-91-8 | Not Assessed under the IRIS program. | ||||||
| 159 | Cyhalothrin/Karate | 68085-85-8 | Not Assessed under the IRIS program. | ||||||
| 160 | Cypermethrin | 52315-07-8 | Not Assessed under the IRIS program. | ||||||
| 161 | Cyromazine | 66215-27-8 | Not Assessed under the IRIS program. | ||||||
| 162 | Dacthal | 1861-32-1 | Not Assessed under the IRIS program. | ||||||
| 163 | Dalapon, sodium salt | 75-99-0 | Not Assessed under the IRIS program. | ||||||
| 164 | Danitol | 39515-41-8 | Not Assessed under the IRIS program. | ||||||
| 165 | 2,2',3,3',4,4',5,5',6,6'-Decabromodiphenyl ether (BDE-209) | 1163-19-5 | Information reviewed but value not estimated. Refer to IRIS Summary. | 0035 | |||||
| 166 | Demeton | 8065-48-3 | Not Assessed under the IRIS program. | ||||||
| 167 | Di (2-ethylhexyl)phthalate (DEHP) | 117-81-7 | Not Assessed under the IRIS program. | ||||||
| 168 | Di(2-ethylhexyl)adipate | 103-23-1 | Not Assessed under the IRIS program. | ||||||
| 169 | 2,4-Diaminotoluene | 95-80-7 | Information reviewed but value not estimated. Refer to IRIS Summary. | 0536 | |||||
| 170 | Diazomethane | 334-88-3 | Information reviewed but value not estimated. Refer to IRIS Summary. | 0616 | |||||
| 171 | Dibenz[a,h]anthracene | 53-70-3 | Not Assessed under the IRIS program. | ||||||
| 172 | Dibenzofuran | 132-64-9 | Not Assessed under the IRIS program. | ||||||
| 173 | 1,2-Dibromo-3-chloropropane (DBCP) | 96-12-8 | Testicular effects | mg /m3 | 2x10-4 | NOAEL (HEC) | 0.17 | Medium | 0414 |
| 174 | 1,4-Dibromobenzene | 106-37-6 | Not Assessed under the IRIS program. | ||||||
| 175 | Dibromochloromethane | 124-48-1 | Not Assessed under the IRIS program. | ||||||
| 176 | Dibromodichloromethane | 594-18-3 | Not Assessed under the IRIS program. | ||||||
| 177 | p,p'-Dibromodiphenyl ether | 2050-47-7 | Not Assessed under the IRIS program. | ||||||
| 178 | 1,2-Dibromoethane | 106-93-4 | Nasal inflammation | mg /m3 | 9x10-3 | BMCL10 (HEC) | 2.8 | Medium | 0361 |
| 179 | Dibutyl phthalate | 84-74-2 | Information reviewed but value not estimated. Refer to IRIS Summary. | 0038 | |||||
| 180 | Dicamba | 1918-00-9 | Not Assessed under the IRIS program. | ||||||
| 181 | Dichloroacetic acid | 79-43-6 | Information reviewed but value not estimated. Refer to IRIS Summary. | 0654 | |||||
| 182 | 1,3-Dichlorobenzene | 541-73-1 | Not Assessed under the IRIS program. | ||||||
| 183 | 1,4-Dichlorobenzene | 106-46-7 | Increased liver weights in P1 males | mg /m3 | 8x10-1 | NOAEL (HEC) | 75 | Medium | 0552 |
| 184 | 1,2-Dichlorobenzene | 95-50-1 | Not Assessed under the IRIS program. | ||||||
| 185 | 3,3'-Dichlorobenzidine | 91-94-1 | Information reviewed but value not estimated. Refer to IRIS Summary. | 0504 | |||||
| 186 | Dichlorodifluoromethane | 75-71-8 | Not Assessed under the IRIS program. | ||||||
| 187 | p,p'-Dichlorodiphenyl dichloroethane (DDD) | 72-54-8 | Not Assessed under the IRIS program. | ||||||
| 188 | p,p'-Dichlorodiphenyldichloroethylene (DDE) | 72-55-9 | Not Assessed under the IRIS program. | ||||||
| 189 | p,p'-Dichlorodiphenyltrichloroethane (DDT) | 50-29-3 | Not Assessed under the IRIS program. | ||||||
| 190 | 1,2-Dichloroethane | 107-06-2 | Not Assessed under the IRIS program. | ||||||
| 191 | 1,1-Dichloroethane | 75-34-3 | Not Assessed under the IRIS program. | ||||||
| 192 | trans-1,2-Dichloroethylene | 156-60-5 | Information reviewed but value not estimated. Refer to IRIS Summary. | 0314 | |||||
| 193 | cis-1,2-Dichloroethylene | 156-59-2 | Information reviewed but value not estimated. Refer to IRIS Summary. | 0418 | |||||
| 194 | 1,1-Dichloroethylene (1,1-DCE) | 75-35-4 | Liver toxicity (fatty change) | mg /m3 | 2x10-1 | BMCL10 (HEC) | 6.9 | Medium | 0039 |
| 195 | Dichloromethane | 75-09-2 | Hepatic effects (hepatic vacuolation) | mg /m3 | 6x10-1 | BMDL10 (HEC) | 17.2 | Medium/High | 0070 |
| 196 | 2,4-Dichlorophenol | 120-83-2 | Not Assessed under the IRIS program. | ||||||
| 197 | 4-(2,4-Dichlorophenoxy)butyric acid (2,4-DB) | 94-82-6 | Not Assessed under the IRIS program. | ||||||
| 198 | 2,4-Dichlorophenoxyacetic acid (2,4-D) | 94-75-7 | Not Assessed under the IRIS program. | ||||||
| 199 | 1,2-Dichloropropane | 78-87-5 | Hyperplasia of the nasal mucosa | mg /m3 | 4x10-3 | LOAEL (HEC) | 1.3 | Medium | 0601 |
| 200 | 2,3-Dichloropropanol | 616-23-9 | Not Assessed under the IRIS program. | ||||||
| 201 | 1,3-Dichloropropene | 542-75-6 | Hypertrophy/ hyperplasia of the nasal respiratory epithelium | mg /m3 | 2x10-2 | BMCL10 (HEC) | 0.72 | High | 0224 |
| 202 | Dichlorvos | 62-73-7 | Decreased brain cholinesterase activity | mg /m3 | 5x10-4 | NOAEL (HEC) | 0.05 | Medium | 0151 |
| 203 | Dicofol | 115-32-2 | Not Assessed under the IRIS program. | ||||||
| 204 | Dieldrin | 60-57-1 | Not Assessed under the IRIS program. | ||||||
| 205 | Diesel engine exhaust | NA | Pulmonary inflammation and histopathology | mg /m3 | 5x10-3 | NOAEL (HEC) | 0.144 | Medium | 0642 |
| 206 | Diethyl phthalate | 84-66-2 | Not Assessed under the IRIS program. | ||||||
| 207 | Diethyl sulfate | 64-67-5 | Information reviewed but value not estimated. Refer to IRIS Summary. | 0615 | |||||
| 208 | Diethyl-p-nitrophenylphosphate | 311-45-5 | Not Assessed under the IRIS program. | ||||||
| 209 | Diethylene glycol dinitrate (DEGDN) | 693-21-0 | Not Assessed under the IRIS program. | ||||||
| 210 | Difenzoquat | 43222-48-6 | Not Assessed under the IRIS program. | ||||||
| 211 | Diflubenzuron | 35367-38-5 | Not Assessed under the IRIS program. | ||||||
| 212 | 1,1-Difluoroethane | 75-37-6 | No adverse effects observed | mg /m3 | 4x101 | NOAEL (HEC) | 12051 | Medium | 0665 |
| 213 | Diisopropyl methylphosphonate (DIMP) | 1445-75-6 | Not Assessed under the IRIS program. | ||||||
| 214 | Dimethipin | 55290-64-7 | Not Assessed under the IRIS program. | ||||||
| 215 | Dimethoate | 60-51-5 | Not Assessed under the IRIS program. | ||||||
| 216 | Dimethyl phthalate | 131-11-3 | Information reviewed but value not estimated. Refer to IRIS Summary. | 0353 | |||||
| 217 | Dimethyl sulfate | 77-78-1 | Information reviewed but value not estimated. Refer to IRIS Summary. | 0365 | |||||
| 218 | Dimethyl terephthalate (DMT) | 120-61-6 | Not Assessed under the IRIS program. | ||||||
| 219 | Dimethylamine | 124-40-3 | Information reviewed but value not estimated. Refer to IRIS Summary. | 0228 | |||||
| 220 | N-N-Dimethylaniline | 121-69-7 | Not Assessed under the IRIS program. | ||||||
| 221 | 3,3-Dimethylbenzidine | 119-93-7 | Information reviewed but value not estimated. Refer to IRIS Summary. | 0538 | |||||
| 222 | N,N-Dimethylformamide | 68-12-2 | Digestive disturbances and minimal hepatic changes suggestive of liver abnormalities | mg /m3 | 3x10-2 | LOAEL (HEC) | 7.9 | Medium | 0511 |
| 223 | 3,4-Dimethylphenol | 95-65-8 | Not Assessed under the IRIS program. | ||||||
| 224 | 2,6-Dimethylphenol | 576-26-1 | Not Assessed under the IRIS program. | ||||||
| 225 | 2,4-Dimethylphenol | 105-67-9 | Not Assessed under the IRIS program. | ||||||
| 226 | 4,6-Dinitro-o-cyclohexyl phenol | 131-89-5 | Not Assessed under the IRIS program. | ||||||
| 227 | m-Dinitrobenzene | 99-65-0 | Not Assessed under the IRIS program. | ||||||
| 228 | o-Dinitrobenzene | 528-29-0 | Not Assessed under the IRIS program. | ||||||
| 229 | 2,4-Dinitrophenol | 51-28-5 | Information reviewed but value not estimated. Refer to IRIS Summary. | 0152 | |||||
| 230 | 2,4-Dinitrotoluene | 121-14-2 | Information reviewed but value not estimated. Refer to IRIS Summary. | 0542 | |||||
| 231 | 2,4-/2,6-Dinitrotoluene mixture | NA | Not Assessed under the IRIS program. | ||||||
| 232 | Dinoseb | 88-85-7 | Not Assessed under the IRIS program. | ||||||
| 233 | 1,4-Dioxane | 123-91-1 | Information reviewed but value not estimated. Refer to IRIS Summary. | 0326 | |||||
| 234 | Diphenamid | 957-51-7 | Not Assessed under the IRIS program. | ||||||
| 235 | Diphenylamine | 122-39-4 | Not Assessed under the IRIS program. | ||||||
| 236 | 1,2-Diphenylhydrazine | 122-66-7 | Information reviewed but value not estimated. Refer to IRIS Summary. | 0049 | |||||
| 237 | Diquat | 85-00-7 | Not Assessed under the IRIS program. | ||||||
| 238 | Disulfoton | 298-04-4 | Not Assessed under the IRIS program. | ||||||
| 239 | 1,4-Dithiane | 505-29-3 | Not Assessed under the IRIS program. | ||||||
| 240 | Diuron | 330-54-1 | Not Assessed under the IRIS program. | ||||||
| 241 | Dodine | 2439-10-3 | Not Assessed under the IRIS program. | ||||||
| 242 | Endosulfan | 115-29-7 | Not Assessed under the IRIS program. | ||||||
| 243 | Endothall | 145-73-3 | Not Assessed under the IRIS program. | ||||||
| 244 | Endrin | 72-20-8 | Not Assessed under the IRIS program. | ||||||
| 245 | Epichlorohydrin | 106-89-8 | Changes in the nasal turbinates | mg /m3 | 1x10-3 | NOAEL (HEC) | 0.36 | Medium | 0050 |
| 246 | 1,2-Epoxybutane (EBU) | 106-88-7 | Degenerative lesions of the nasal cavity | mg /m3 | 2x10-2 | LOAEL (HEC) | 4.8 | Medium | 0630 |
| 247 | Ethephon | 16672-87-0 | Not Assessed under the IRIS program. | ||||||
| 248 | Ethion | 563-12-2 | Not Assessed under the IRIS program. | ||||||
| 249 | 2-Ethoxyethanol | 110-80-5 | Decreased testis weight, seminiferous tubule degeneration and decreased hemoglobin | mg /m3 | 2x10-1 | NOAEL (HEC) | 68 | Medium | 0513 |
| 250 | Ethyl acetate | 141-78-6 | Not Assessed under the IRIS program. | ||||||
| 251 | Ethyl carbamate | 51-79-6 | Information reviewed but value not estimated. Refer to IRIS Summary. | 0629 | |||||
| 252 | Ethyl chloride | 75-00-3 | Delayed fetal ossification | mg /m3 | 1x101<7sup> | NOAEL (HEC) | 4000 | Medium | 0523 |
| 253 | S-Ethyl dipropylthiocarbamate (EPTC) | 759-94-4 | Not Assessed under the IRIS program. | ||||||
| 254 | Ethyl ether | 60-29-7 | Not Assessed under the IRIS program. | ||||||
| 255 | Ethyl p-nitrophenyl phenylphosphorothioate (EPN) | 2104-64-5 | Not Assessed under the IRIS program. | ||||||
| 256 | Ethylbenzene | 100-41-4 | Developmental toxicity | mg /m3 | 1 | NOAEL (HEC) | 434 | Low | 0051 |
| 257 | Ethylene diamine | 107-15-3 | Information reviewed but value not estimated. Refer to IRIS Summary. | 0528 | |||||
| 258 | Ethylene glycol | 107-21-1 | Not Assessed under the IRIS program. | ||||||
| 259 | Ethylene glycol monobutyl ether (EGBE) (2-Butoxyethanol) | 111-76-2 | Hemosiderin deposition in the liver | mg /m3 | 1.6 | BMCL (HEC) | 16 | Medium/High | 0500 |
| 260 | Ethylene thiourea (ETU) | 96-45-7 | Not Assessed under the IRIS program. | ||||||
| 261 | Ethyleneimine | 151-56-4 | Information reviewed but value not estimated. Refer to IRIS Summary. | 0631 | |||||
| 262 | Ethylphthalyl ethylglycolate (EPEG) | 84-72-0 | Not Assessed under the IRIS program. | ||||||
| 263 | Express | 101200-48-0 | Not Assessed under the IRIS program. | ||||||
| 264 | Fenamiphos | 22224-92-6 | Not Assessed under the IRIS program. | ||||||
| 265 | Fluometuron | 2164-17-2 | Not Assessed under the IRIS program. | ||||||
| 266 | Fluoranthene | 206-44-0 | Not Assessed under the IRIS program. | ||||||
| 267 | Fluorene | 86-73-7 | Not Assessed under the IRIS program. | ||||||
| 268 | Fluorine (soluble fluoride) | 7782-41-4 | Not Assessed under the IRIS program. | ||||||
| 269 | Fluridone | 59756-60-4 | Not Assessed under the IRIS program. | ||||||
| 270 | Flurprimidol | 56425-91-3 | Not Assessed under the IRIS program. | ||||||
| 271 | Flutolanil | 66332-96-5 | Not Assessed under the IRIS program. | ||||||
| 272 | Fluvalinate | 69409-94-5 | Not Assessed under the IRIS program. | ||||||
| 273 | Folpet | 133-07-3 | Not Assessed under the IRIS program. | ||||||
| 274 | Fomesafen | 72178-02-0 | Not Assessed under the IRIS program. | ||||||
| 275 | Fonofos | 944-22-9 | Not Assessed under the IRIS program. | ||||||
| 276 | Formaldehyde | 50-00-0 | Not Assessed under the IRIS program. | ||||||
| 277 | Formic acid | 64-18-6 | Not Assessed under the IRIS program. | ||||||
| 278 | Fosetyl-al | 39148-24-8 | Not Assessed under the IRIS program. | ||||||
| 279 | Furan | 110-00-9 | Not Assessed under the IRIS program. | ||||||
| 280 | Furfural | 98-01-1 | Not Assessed under the IRIS program. | ||||||
| 281 | Furmecyclox | 60568-05-0 | Not Assessed under the IRIS program. | ||||||
| 282 | Glufosinate-ammonium | 77182-82-2 | Not Assessed under the IRIS program. | ||||||
| 283 | Glycidaldehyde | 765-34-4 | Not Assessed under the IRIS program. | ||||||
| 284 | Glyphosate | 1071-83-6 | Not Assessed under the IRIS program. | ||||||
| 285 | Haloxyfop-methyl | 69806-40-2 | Not Assessed under the IRIS program. | ||||||
| 286 | Harmony | 79277-27-3 | Not Assessed under the IRIS program. | ||||||
| 287 | Heptachlor | 76-44-8 | Not Assessed under the IRIS program. | ||||||
| 288 | Heptachlor epoxide | 1024-57-3 | Not Assessed under the IRIS program. | ||||||
| 289 | n-Heptane | 142-82-5 | Not Assessed under the IRIS program. | ||||||
| 290 | Hexabromobenzene | 87-82-1 | Not Assessed under the IRIS program. | ||||||
| 291 | Hexabromodiphenyl ether | 36483-60-0 | Not Assessed under the IRIS program. | ||||||
| 292 | 2,2',4,4',5,5'-Hexabromodiphenyl ether (BDE-153) | 68631-49-2 | Information reviewed but value not estimated. Refer to IRIS Summary. | 1009 | |||||
| 293 | Hexachlorobenzene | 118-74-1 | Information reviewed but value not estimated. Refer to IRIS Summary. | 0374 | |||||
| 294 | Hexachlorobutadiene | 87-68-3 | Not Assessed under the IRIS program. | ||||||
| 295 | alpha-Hexachlorocyclohexane (alpha-HCH) | 319-84-6 | Not Assessed under the IRIS program. | ||||||
| 296 | beta-Hexachlorocyclohexane (beta-HCH) | 319-85-7 | Not Assessed under the IRIS program. | ||||||
| 297 | delta-Hexachlorocyclohexane (delta-HCH) | 319-86-8 | Not Assessed under the IRIS program. | ||||||
| 298 | epsilon-Hexachlorocyclohexane (epsilon-HC) | 6108-10-7 | Not Assessed under the IRIS program. | ||||||
| 299 | gamma-Hexachlorocyclohexane (gamma-HCH) | 58-89-9 | Not Assessed under the IRIS program. | ||||||
| 300 | technical Hexachlorocyclohexane (t-HCH) | 608-73-1 | Not Assessed under the IRIS program. | ||||||
| 301 | Hexachlorocyclopentadiene (HCCPD) | 77-47-4 | Suppurative inflammation of the nose | mg /m3 | 2x10-4 | NOAEL (HEC) | 0.024 | Medium | 0059 |
| 302 | Hexachlorodibenzo-p-dioxin (HxCDD), mixture of 1,2,3,6,7,8-HxCDD and 1,2,3,7,8,9-HxCDD | 57653-85-7 | Not Assessed under the IRIS program. | ||||||
| 303 | Hexachloroethane | 67-72-1 | Neurotoxicity (tremors and ruffled pelt) | mg /m3 | 3x10-2 | NOAEL (HEC) | 83 | Low | 0167 |
| 304 | Hexachlorophene | 70-30-4 | Not Assessed under the IRIS program. | ||||||
| 305 | Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) | 121-82-4 | Not Assessed under the IRIS program. | ||||||
| 306 | 1,6-Hexamethylene diisocyanate | 822-06-0 | Degeneration of olfactory epithelium | mg /m3| 1x10-5 | NOAEL (HEC) | 0.001 | Medium | 0638 | |
| 307 | n-Hexane | 110-54-3 | Peripheral neuropathy (decreased MCV at 12 weeks) | mg /m3 | 7x10-1 | BMCL (HEC) | 215 | Medium | 0486 |
| 308 | 2-Hexanone | 591-78-6 | Motor conduction velocity of the sciatic-tibial nerve | mg /m3 | 3x10-2 | BMCL05 (HEC) | 90 | Low | 1019 |
| 309 | Hexazinone | 51235-04-2 | Not Assessed under the IRIS program. | ||||||
| 310 | Hydrazine/Hydrazine sulfate | 302-01-2 | Not Assessed under the IRIS program. | ||||||
| 311 | Hydrogen Cyanide and Cyanide Salts | Various | Thyroid enlargement and altered iodide uptake | mg /m3 | 0.0008 | LOAEL (ADJ) | 2.5 | Low/Medium | 0060 |
| 312 | Hydrogen chloride | 7647-01-0 | Hyperplasia of nasal mucosa larynx and trachea | mg /m3 | 2x10-2 | LOAEL (HEC) | 6.1 | Low | 0396 |
| 313 | Hydrogen sulfide | 7783-06-4 | Nasal lesions of the olfactory mucosa | mg /m3 | 2x10-3 | NOAEL (HEC) | 0.64 | Medium/High | 0061 |
| 314 | Hydroquinone | 123-31-9 | Information reviewed but value not estimated. Refer to IRIS Summary. | ||||||
| 315 | Imazalil | 35554-44-0 | Not Assessed under the IRIS program. | ||||||
| 316 | Imazaquin | 81335-37-7 | Not Assessed under the IRIS program. | ||||||
| 317 | Indeno[1,2,3-cd]pyrene | 193-39-5 | Not Assessed under the IRIS program. | ||||||
| 318 | Iprodione | 36734-19-7 | Not Assessed under the IRIS program. | ||||||
| 319 | Isobutyl alcohol | 78-83-1 | Not Assessed under the IRIS program. | ||||||
| 320 | Isophorone | 78-59-1 | Information reviewed but value not estimated. Refer to IRIS Summary. | ||||||
| 321 | Isopropalin | 33820-53-0 | Not Assessed under the IRIS program. | ||||||
| 322 | Isopropyl methyl phosphonic acid (IMPA) | 1832-54-8 | Not Assessed under the IRIS program. | ||||||
| 323 | Isoxaben | 82558-50-7 | Not Assessed under the IRIS program. | ||||||
| 324 | Lactofen | 77501-63-4 | Not Assessed under the IRIS program. | ||||||
| 325 | Lead and compounds (inorganic) | 7439-92-1 | Not Assessed under the IRIS program. | ||||||
| 326 | d-Limonene | 5989-27-5 | Information reviewed but value not estimated. Refer to IRIS Summary. | ||||||
| 327 | Linuron | 330-55-2 | Not Assessed under the IRIS program. | ||||||
| 328 | Londax | 83055-99-6 | Not Assessed under the IRIS program. | ||||||
| 329 | Malathion | 121-75-5 | Not Assessed under the IRIS program. | ||||||
| 330 | Maleic anhydride | 108-31-6 | Not Assessed under the IRIS program. | ||||||
| 331 | Maleic hydrazide | 123-33-1 | Not Assessed under the IRIS program. | ||||||
| 332 | Maneb | 12427-38-2 | Not Assessed under the IRIS program. | ||||||
| 333 | Manganese | 7439-96-5 | Impairment of neurobehavioral function (other effect: Impairment of neurobehavioral function) | mg /m3 | 5x10-5 | LOAEL (HEC) | 0.05 | Medium | 0373 |
| 334 | Mepiquat chloride | 24307-26-4 | Not Assessed under the IRIS program. | ||||||
| 335 | Mercuric chloride (HgCl2) | 7487-94-7 | Not Assessed under the IRIS program. | ||||||
| 336 | Mercury, elemental | 7439-97-6 | Hand tremor; increases in memory disturbances; slight subjective and objective evidence of autonomic dysfunction | mg /m3 | 3x10-4 | LOAEL (ADJ) | 0.009 | Medium | 0370 |
| 337 | Merphos | 150-50-5 | Information reviewed but value not estimated. Refer to IRIS Summary. | ||||||
| 338 | Merphos oxide | 78-48-8 | Information reviewed but value not estimated. Refer to IRIS Summary. | ||||||
| 339 | Metalaxyl | 57837-19-1 | Not Assessed under the IRIS program. | ||||||
| 340 | Methacrylonitrile | 126-98-7 | Not Assessed under the IRIS program. | ||||||
| 341 | Methamidophos | 10265-92-6 | Not Assessed under the IRIS program. | ||||||
| 342 | Methanol | 67-56-1 | Not Assessed under the IRIS program. | ||||||
| 343 | Methidathion | 950-37-8 | Not Assessed under the IRIS program. | ||||||
| 344 | Methomyl | 16752-77-5 | Not Assessed under the IRIS program. | ||||||
| 345 | Methoxychlor | 72-43-5 | Information reviewed but value not estimated. Refer to IRIS Summary. | ||||||
| 346 | 2-Methoxyethanol | 109-86-4 | Testicular effects | mg /m3 | 2x10-2 | NOAEL (HEC) | 17 | Medium | 0525 |
| 347 | Methyl acrylate | 96-33-3 | Not Assessed under the IRIS program. | ||||||
| 348 | Methyl chloride | 74-87-3 | Cerebellar lesions | mg /m3 | 9x10-2 | NOAEL (HEC) | 94.6 | Medium | 1003 |
| 349 | Methyl chlorocarbonate | 79-22-1 | Not Assessed under the IRIS program. | ||||||
| 350 | Methyl ethyl ketone (MEK) | 78-93-3 | Developmental toxicity (skeletal variations) | mg /m3 | 5 | LEC (HEC) | 1517 | Medium | 0071 |
| 351 | Methyl iodide | 74-88-4 | Not Assessed under the IRIS program. | ||||||
| 352 | Methyl isobutyl ketone (MIBK) | 108-10-1 | Reduced fetal body weight, skeletal variations, and increased fetal death in mice, and skeletal variations in rats | mg /m3 | 3 | NOAEL (HEC) | 1026 | Low/Medium | 0173 |
| 353 | Methyl isocyanate | 624-83-9 | Information reviewed but value not estimated. Refer to IRIS Summary. | ||||||
| 354 | Methyl methacrylate | 80-62-6 | Degeneration/ atrophy of olfactory epithelium (male rats) | mg /m3 | 7x10-1 | BMC10 (HEC) | 7.2 | Medium/High | 1000 |
| 355 | Methyl parathion | 298-00-0 | Not Assessed under the IRIS program. | ||||||
| 356 | Methyl tert-butyl ether (MTBE) | 1634-04-4 | Increased absolute and relative liver and kidney weights and increased severity of spontaneous renal lesions (females), increased prostration (females), and swollen periocular tissue (males and females) | mg /m3 | 3 | NOAEL (HEC) | 259 | Medium | 0545 |
| 357 | 4-(2-Methyl-4-chlorophenoxy) butyric acid (MCPB) | 94-81-5 | Not Assessed under the IRIS program. | ||||||
| 358 | 2-(2-Methyl-4-chlorophenoxy)propionic acid (MCPP) | 93-65-2 | Not Assessed under the IRIS program. | ||||||
| 359 | 2-Methyl-4-chlorophenoxyacetic acid (MCPA) | 94-74-6 | Not Assessed under the IRIS program. | ||||||
| 360 | Methylene Diphenyl Diisocyanate (monomeric MDI) and polymeric MDI (PMDI) | 101-68-8 | Hyperplasia of olfactory epithelium | mg /m3 | 6x10-4 | BMC10 (HEC) | 0.06 | Medium | 0529 |
| 361 | 4,4'-Methylene bis(N,N'-dimethyl)aniline | 101-61-1 | Not Assessed under the IRIS program. | ||||||
| 362 | Methylmercury (MeHg) | 22967-92-6 | Not Assessed under the IRIS program. | ||||||
| 363 | 2-Methylnaphthalene | 91-57-6 | Information reviewed but value not estimated. Refer to IRIS Summary. | ||||||
| 364 | 4-Methylphenol | 106-44-5 | Information reviewed but value not estimated. Refer to IRIS Summary. | ||||||
| 365 | 3-Methylphenol | 108-39-4 | Information reviewed but value not estimated. Refer to IRIS Summary. | ||||||
| 366 | 2-Methylphenol | 95-48-7 | Information reviewed but value not estimated. Refer to IRIS Summary. | ||||||
| 367 | Metolachlor | 51218-45-2 | Not Assessed under the IRIS program. | ||||||
| 368 | Metribuzin | 21087-64-9 | Not Assessed under the IRIS program. | ||||||
| 369 | Mirex | 2385-85-5 | Not Assessed under the IRIS program. | ||||||
| 370 | Molinate | 2212-67-1 | Not Assessed under the IRIS program. | ||||||
| 371 | Molybdenum | 7439-98-7 | Not Assessed under the IRIS program. | ||||||
| 372 | Monochloramine | 10599-90-3 | Not Assessed under the IRIS program. | ||||||
| 373 | Naled | 300-76-5 | Not Assessed under the IRIS program. | ||||||
| 374 | Naphthalene | 91-20-3 | Nasal effects: hyperplasia and metaplasia in respiratory and olfactory epithelium, respectively | mg /m3 | 3x10-3 | LOAEL (HEC) | 9.3 | Medium | 0436 |
| 375 | Napropamide | 15299-99-7 | Not Assessed under the IRIS program. | ||||||
| 376 | Nickel carbonyl | 13463-39-3 | Not Assessed under the IRIS program. | ||||||
| 377 | Nickel refinery dust | NA | Not Assessed under the IRIS program. | ||||||
| 378 | Nickel subsulfide | 12035-72-2 | Not Assessed under the IRIS program. | ||||||
| 379 | Nickel, soluble salts | NA | Not Assessed under the IRIS program. | ||||||
| 380 | Nitrapyrin | 1929-82-4 | Not Assessed under the IRIS program. | ||||||
| 381 | Nitrate | 14797-55-8 | Not Assessed under the IRIS program. | ||||||
| 382 | Nitric oxide | 10102-43-9 | Not Assessed under the IRIS program. | ||||||
| 383 | Nitrite | 14797-65-0 | Not Assessed under the IRIS program. | ||||||
| 384 | Nitrobenzene | 98-95-3 | Bronchiolization of the alveoli and olfactory degeneration | mg /m3 | 9x10-3 | BMCL10 (HEC) | 0.26 | Medium | 0079 |
| 385 | Nitrogen dioxide | 10102-44-0 | Information reviewed but value not estimated. Refer to IRIS Summary. | ||||||
| 386 | Nitroguanidine | 556-88-7 | Not Assessed under the IRIS program. | ||||||
| 387 | p-Nitrophenol | 100-02-7 | Information reviewed but value not estimated. Refer to IRIS Summary. | ||||||
| 388 | 2-Nitropropane | 79-46-9 | Liver focal vacuolization and nodules | mg /m3 | 2x10-2 | LOAEL (HEC) | 16 | Low | 0519 |
| 389 | N-Nitroso-N-methylethylamine | 10595-95-6 | Not Assessed under the IRIS program. | ||||||
| 390 | N-Nitroso-di-n-butylamine | 924-16-3 | Not Assessed under the IRIS program. | ||||||
| 391 | N-Nitrosodi-N-propylamine | 621-64-7 | Not Assessed under the IRIS program. | ||||||
| 392 | N-Nitrosodiethanolamine | 1116-54-7 | Not Assessed under the IRIS program. | ||||||
| 393 | N-Nitrosodiethylamine | 55-18-5 | Not Assessed under the IRIS program. | ||||||
| 394 | N-Nitrosodimethylamine | 62-75-9 | Not Assessed under the IRIS program. | ||||||
| 395 | N-Nitrosodiphenylamine | 86-30-6 | Not Assessed under the IRIS program. | ||||||
| 396 | N-Nitrosopyrrolidine | 930-55-2 | Not Assessed under the IRIS program. | ||||||
| 397 | Nonabromodiphenyl ether | 63936-56-1 | Not Assessed under the IRIS program. | ||||||
| 398 | Norflurazon | 27314-13-2 | Not Assessed under the IRIS program. | ||||||
| 399 | NuStar | 85509-19-9 | Not Assessed under the IRIS program. | ||||||
| 400 | Octabromodiphenyl ether | 32536-52-0 | Not Assessed under the IRIS program. | ||||||
| 401 | Octahydro-1,3,5,7-tetranitro-1,3,5,7-tetrazocine (HMX) | 2691-41-0 | Not Assessed under the IRIS program. | ||||||
| 402 | Oryzalin | 19044-88-3 | Not Assessed under the IRIS program. | ||||||
| 403 | Oxadiazon | 19666-30-9 | Not Assessed under the IRIS program. | ||||||
| 404 | Oxamyl | 23135-22-0 | Not Assessed under the IRIS program. | ||||||
| 405 | Oxyfluorfen | 42874-03-3 | Not Assessed under the IRIS program. | ||||||
| 406 | Paclobutrazol | 76738-62-0 | Not Assessed under the IRIS program. | ||||||
| 407 | Paraquat | 1910-42-5 | Not Assessed under the IRIS program. | ||||||
| 408 | Parathion | 56-38-2 | Not Assessed under the IRIS program. | ||||||
| 409 | Pendimethalin | 40487-42-1 | Not Assessed under the IRIS program. | ||||||
| 410 | Pentabromodiphenyl ether | 32534-81-9 | Not Assessed under the IRIS program. | ||||||
| 411 | 2,2',4,4',5-Pentabromodiphenyl ether (BDE-99) | 60348-60-9 | Information reviewed but value not estimated. Refer to IRIS Summary. | ||||||
| 412 | Pentachlorobenzene | 608-93-5 | Not Assessed under the IRIS program. | ||||||
| 413 | Pentachlorocyclopentadiene | 25329-35-5 | Not Assessed under the IRIS program. | ||||||
| 414 | Pentachloronitrobenzene (PCNB) | 82-68-8 | Not Assessed under the IRIS program. | ||||||
| 415 | Pentachlorophenol | 87-86-5 | Information reviewed but value not estimated. Refer to IRIS Summary. | ||||||
| 416 | Pentafluoroethane | 354-33-6 | Information reviewed but value not estimated. Refer to IRIS Summary. | ||||||
| 417 | Perchlorate (ClO4) and Perchlorate Salts | 7790-98-9 | Information reviewed but value not estimated. Refer to IRIS Summary. | ||||||
| 418 | Permethrin | 52645-53-1 | Not Assessed under the IRIS program. | ||||||
| 419 | Phenanthrene | 85-01-8 | Not Assessed under the IRIS program. | ||||||
| 420 | Phenmedipham | 13684-63-4 | Not Assessed under the IRIS program. | ||||||
| 421 | Phenol | 108-95-2 | Information reviewed but value not estimated. Refer to IRIS Summary. | ||||||
| 422 | m-Phenylenediamine | 108-45-2 | Not Assessed under the IRIS program. | ||||||
| 423 | Phenylmercuric acetate | 62-38-4 | Not Assessed under the IRIS program. | ||||||
| 424 | Phosalone | 2310-17-0 | Not Assessed under the IRIS program. | ||||||
| 425 | Phosgene | 75-44-5 | Collagen staining indicative of fibrosis | mg /m3 | 3x10-4 | BMDL10 (HEC) | 0.03 | Medium | 0487 |
| 426 | Phosmet | 732-11-6 | Not Assessed under the IRIS program. | ||||||
| 427 | Phosphine | 7803-51-2 | Decreased body weight | mg /m3 | 3x10-4 | NOAEL (HEC) | 0.25 | Low | 0090 |
| 428 | Phosphoric acid | 7664-38-2 | Bronchiolar fibrosis | mg /m3 | 1x10-2 | BMC10 (HEC) | 3.4 | Medium | 0697 |
| 429 | Phthalic anhydride | 85-44-9 | Not Assessed under the IRIS program. | ||||||
| 430 | Picloram | 1918-02-1 | Not Assessed under the IRIS program. | ||||||
| 431 | Pirimiphos-methyl | 29232-93-7 | Not Assessed under the IRIS program. | ||||||
| 432 | Polychlorinated biphenyls (PCBs) | 1336-36-3 | Not Assessed under the IRIS program. | ||||||
| 433 | Potassium cyanide | 151-50-8 | Not Assessed under the IRIS program. | ||||||
| 434 | Potassium silver cyanide | 506-61-6 | Not Assessed under the IRIS program. | ||||||
| 435 | Prochloraz | 67747-09-5 | Not Assessed under the IRIS program. | ||||||
| 436 | Prometon | 1610-18-0 | Not Assessed under the IRIS program. | ||||||
| 437 | Prometryn | 7287-19-6 | Not Assessed under the IRIS program. | ||||||
| 438 | Pronamide | 23950-58-5 | Not Assessed under the IRIS program. | ||||||
| 439 | Propachlor | 1918-16-7 | Not Assessed under the IRIS program. | ||||||
| 440 | Propanil | 709-98-8 | Not Assessed under the IRIS program. | ||||||
| 441 | Propargite | 2312-35-8 | Not Assessed under the IRIS program. | ||||||
| 442 | Propargyl alcohol | 107-19-7 | Not Assessed under the IRIS program. | ||||||
| 443 | Propazine | 139-40-2 | Not Assessed under the IRIS program. | ||||||
| 444 | Propham | 122-42-9 | Not Assessed under the IRIS program. | ||||||
| 445 | Propiconazole | 60207-90-1 | Not Assessed under the IRIS program. | ||||||
| 446 | beta-Propiolactone | 57-57-8 | Information reviewed but value not estimated. Refer to IRIS Summary. | ||||||
| 447 | Propionaldehyde | 123-38-6 | Atrophy of olfactory epithelium | mg /m3 | 8x10-3 | BMCL10 (HEC) | 8 | Low/Medium | 1011 |
| 448 | Propylene glycol | 57-55-6 | Information reviewed but value not estimated. Refer to IRIS Summary. | ||||||
| 449 | Propylene glycol monoethyl ether | 52125-53-8 | Information reviewed but value not estimated. Refer to IRIS Summary. | ||||||
| 450 | Propylene glycol monomethyl ether (PGME) | 107-98-2 | Mild reversible sedation | mg /m3 | 2 | NOAEL (HEC) | 658 | Medium | 0404 |
| 451 | Propylene oxide | 75-56-9 | Nest-like infolds of the nasal respiratory epithelium | mg /m3 | 3x10-2 | LOAEL (HEC) | 2.9 | Medium | 0403 |
| 452 | Propyleneimine | 75-55-8 | Information reviewed but value not estimated. Refer to IRIS Summary. | ||||||
| 453 | Pursuit | 81335-77-5 | Not Assessed under the IRIS program. | ||||||
| 454 | Pydrin | 51630-58-1 | Not Assessed under the IRIS program. | ||||||
| 455 | Pyrene | 129-00-0 | Not Assessed under the IRIS program. | ||||||
| 456 | Pyridine | 110-86-1 | Not Assessed under the IRIS program. | ||||||
| 457 | Quinalphos | 13593-03-8 | Not Assessed under the IRIS program. | ||||||
| 458 | Quinoline | 91-22-5 | Information reviewed but value not estimated. Refer to IRIS Summary. | ||||||
| 459 | Quinone | 106-51-4 | Information reviewed but value not estimated. Refer to IRIS Summary. | ||||||
| 460 | Radium 226,228 | 7440-14-4 | Not Assessed under the IRIS program. | ||||||
| 461 | Radon 222 | 14859-67-7 | Not Assessed under the IRIS program. | ||||||
| 462 | Refractory ceramic fibers | NA | Not Assessed under the IRIS program. | ||||||
| 463 | Resmethrin | 10453-86-8 | Not Assessed under the IRIS program. | ||||||
| 464 | Rotenone | 83-79-4 | Not Assessed under the IRIS program. | ||||||
| 465 | Savey | 78587-05-0 | Not Assessed under the IRIS program. | ||||||
| 466 | Selenious acid | 7783-00-8 | Not Assessed under the IRIS program. | ||||||
| 467 | Selenium and Compounds | 7782-49-2 | Not Assessed under the IRIS program. | ||||||
| 468 | Selenium sulfide | 7446-34-6 | Not Assessed under the IRIS program. | ||||||
| 469 | Selenourea | 630-10-4 | Not Assessed under the IRIS program. | ||||||
| 470 | Sethoxydim | 74051-80-2 | Not Assessed under the IRIS program. | ||||||
| 471 | Silver | 7440-22-4 | Not Assessed under the IRIS program. | ||||||
| 472 | Silver cyanide | 506-64-9 | Not Assessed under the IRIS program. | ||||||
| 473 | Simazine | 122-34-9 | Not Assessed under the IRIS program. | ||||||
| 474 | Sodium azide | 26628-22-8 | Not Assessed under the IRIS program. | ||||||
| 475 | Sodium cyanide | 143-33-9 | Not Assessed under the IRIS program. | ||||||
| 476 | Sodium diethyldithiocarbamate | 148-18-5 | Not Assessed under the IRIS program. | ||||||
| 477 | Sodium fluoroacetate | 62-74-8 | Not Assessed under the IRIS program. | ||||||
| 478 | Strontium | 7440-24-6 | Not Assessed under the IRIS program. | ||||||
| 479 | Strychnine | 57-24-9 | Not Assessed under the IRIS program. | ||||||
| 480 | Styrene | 100-42-5 | CNS effects | mg /m3 | 1 | NOAEL (HEC) | 34 | Medium | 0104 |
| 481 | Systhane | 88671-89-0 | Not Assessed under the IRIS program. | ||||||
| 482 | Tebuthiuron | 34014-18-1 | Not Assessed under the IRIS program. | ||||||
| 483 | Terbacil | 5902-51-2 | Not Assessed under the IRIS program. | ||||||
| 484 | Terbutryn | 886-50-0 | Not Assessed under the IRIS program. | ||||||
| 485 | Tetrabromodiphenyl ether | 40088-47-9 | Not Assessed under the IRIS program. | ||||||
| 486 | 2,2',4,4'-Tetrabromodiphenyl ether (BDE-47) | 5436-43-1 | Information reviewed but value not estimated. Refer to IRIS Summary. | ||||||
| 487 | 1,2,4,5-Tetrachlorobenzene | 95-94-3 | Not Assessed under the IRIS program. | ||||||
| 488 | Tetrachlorocyclopentadiene | 695-77-2 | Not Assessed under the IRIS program. | ||||||
| 489 | 2,3,7,8-Tetrachlorodibenzo-p-dioxin | 1746-01-6 | Not Assessed under the IRIS program. | ||||||
| 490 | 1,1,1,2-Tetrachloroethane | 630-20-6 | Not Assessed under the IRIS program. | ||||||
| 491 | 1,1,2,2-Tetrachloroethane | 79-34-5 | Information reviewed but value not estimated. Refer to IRIS Summary. | ||||||
| 492 | Tetrachloroethylene | 127-18-4 | Not Assessed under the IRIS program. | ||||||
| 493 | 2,3,4,6-Tetrachlorophenol | 58-90-2 | Not Assessed under the IRIS program. | ||||||
| 494 | Tetrachlorovinphos | 961-11-5 | Not Assessed under the IRIS program. | ||||||
| 495 | Tetraethyl lead | 78-00-2 | Not Assessed under the IRIS program. | ||||||
| 496 | Tetraethyldithiopyrophosphate | 3689-24-5 | Not Assessed under the IRIS program. | ||||||
| 497 | 1,1,1,2-Tetrafluoroethane | 811-97-2 | Leydig cell hyperplasia | mg /m3 | 8x101 | BMC10 (HEC) | 8200 | Medium | 0656 |
| 498 | Thallium (I), soluble salts | Various | Information reviewed but value not estimated. Refer to IRIS Summary. | ||||||
| 499 | Thallium acetate | 563-68-8 | Information reviewed but value not estimated. Refer to IRIS Summary. | ||||||
| 500 | Thallium carbonate | 6533-73-9 | Information reviewed but value not estimated. Refer to IRIS Summary. | ||||||
| 501 | Thallium chloride | 7791-12-0 | Information reviewed but value not estimated. Refer to IRIS Summary. | ||||||
| 502 | Thallium nitrate | 10102-45-1 | Information reviewed but value not estimated. Refer to IRIS Summary. | ||||||
| 503 | Thallium oxide | 1314-32-5 | Information reviewed but value not estimated. Refer to IRIS Summary. | ||||||
| 504 | Thallium selenite | 12039-52-0 | Information reviewed but value not estimated. Refer to IRIS Summary. | ||||||
| 505 | Thallium(I) sulfate | 7446-18-6 | Information reviewed but value not estimated. Refer to IRIS Summary. | ||||||
| 506 | Thiobencarb | 28249-77-6 | Not Assessed under the IRIS program. | ||||||
| 507 | Thiophanate-methyl | 23564-05-8 | Not Assessed under the IRIS program. | ||||||
| 508 | Thiram | 137-26-8 | Not Assessed under the IRIS program. | ||||||
| 509 | Toluene | 108-88-3 | Neurological effects in occupationally-exposed workers (other effect:) | mg /m3 | 5 | NOAEL (ADJ) | 46 | High | 0118 |
| 510 | 2,4-/2,6-Toluene diisocyanate mixture (TDI) | 26471-62-5 | Chronic lung-function decline | mg /m3 | 7x10-5 | NOAEL (HEC) | 0.002 | Medium | 0503 |
| 511 | Toxaphene | 8001-35-2 | Not Assessed under the IRIS program. | ||||||
| 512 | Tralomethrin | 66841-25-6 | Not Assessed under the IRIS program. | ||||||
| 513 | Triallate | 2303-17-5 | Not Assessed under the IRIS program. | ||||||
| 514 | Triasulfuron | 82097-50-5 | Not Assessed under the IRIS program. | ||||||
| 515 | 1,2,4-Tribromobenzene | 615-54-3 | Not Assessed under the IRIS program. | ||||||
| 516 | Tribromochloromethane | 594-15-0 | Not Assessed under the IRIS program. | ||||||
| 517 | Tribromodiphenyl ether | 49690-94-0 | Not Assessed under the IRIS program. | ||||||
| 518 | Tributyltin oxide (TBTO) | 56-35-9 | Information reviewed but value not estimated. Refer to IRIS Summary. | ||||||
| 519 | 1,1,2-Trichloro-1,2,2-trifluoroethane (CFC-113) | 76-13-1 | Not Assessed under the IRIS program. | ||||||
| 520 | Trichloroacetic acid | 76-03-9 | Information reviewed but value not estimated. Refer to IRIS Summary. | ||||||
| 521 | 1,2,4-Trichlorobenzene | 120-82-1 | Not Assessed under the IRIS program. | ||||||
| 522 | Trichlorocyclopentadiene | 77323-84-3 | Not Assessed under the IRIS program. | ||||||
| 523 | 1,1,2-Trichloroethane | 79-00-5 | Not Assessed under the IRIS program. | ||||||
| 524 | 1,1,1-Trichloroethane | 71-55-6 | Liver histopathologic changes | mg /m3 | 5 | NOEL (HEC) | 1553 | Medium | 0197 |
| 525 | Trichloroethylene | 79-01-6 | Decreased thymus weight in female B6C3F1 mice (immunotoxicity) | mg /m3 | 0.002 | LOAEL (HEC99) | 0.19 | High | 0199 |
| 526 | Trichloroethylene | 79-01-6 | Increased fetal cardiac malformations in Sprague-Dawley rats (heart malformations) | mg /m3 | 0.002 | BMDL01 (HEC99) | 0.021 | High | 0199 |
| 527 | Trichlorofluoromethane | 75-69-4 | Not Assessed under the IRIS program. | ||||||
| 528 | 2,4,5-Trichlorophenol | 95-95-4 | Information reviewed but value not estimated. Refer to IRIS Summary. | ||||||
| 529 | 2,4,6-Trichlorophenol | 88-06-2 | Information reviewed but value not estimated. Refer to IRIS Summary. | ||||||
| 530 | 2(2,4,5-Trichlorophenoxy) propionic acid (2,4,5-TP) | 93-72-1 | Not Assessed under the IRIS program. | ||||||
| 531 | 2,4,5-Trichlorophenoxyacetic acid (2,4,5-T) | 93-76-5 | Not Assessed under the IRIS program. | ||||||
| 532 | 1,1,2-Trichloropropane | 598-77-6 | Not Assessed under the IRIS program. | ||||||
| 533 | 1,2,3-Trichloropropane | 96-18-4 | peribronchial lymphoid hyperplasia in male rats | mg /m3 | 0.0003 | BMCL (HEC) | 0.90 | Low | 0200 |
| 534 | Tricresol | 1319-77-3 | Information reviewed but value not estimated. Refer to IRIS Summary. | ||||||
| 535 | Tridiphane | 58138-08-2 | Not Assessed under the IRIS program. | ||||||
| 536 | Triethylamine | 121-44-8 | No observed adverse effects (other effect: Inflammation of the nasal passage) | mg /m3 | 7x10-3 | NOAEL (HEC) | 19.5 | Low | 0520 |
| 537 | Triethylene glycol monobutyl ether | 143-22-6 | Information reviewed but value not estimated. Refer to IRIS Summary. | ||||||
| 538 | Triethylene glycol monoethyl ether | 112-50-5 | Information reviewed but value not estimated. Refer to IRIS Summary. | ||||||
| 539 | Trifluralin | 1582-09-8 | Not Assessed under the IRIS program. | ||||||
| 540 | 2,2,4-Trimethylpentane | 540-84-1 | Information reviewed but value not estimated. Refer to IRIS Summary. | ||||||
| 541 | 1,3,5-Trinitrobenzene | 99-35-4 | Not Assessed under the IRIS program. | ||||||
| 542 | 2,4,6-Trinitrotoluene (TNT) | 118-96-7 | Not Assessed under the IRIS program. | ||||||
| 543 | Uranium, natural | 7440-61-1 | Not Assessed under the IRIS program. | ||||||
| 544 | Uranium, soluble salts | NA | Not Assessed under the IRIS program. | ||||||
| 545 | Urea | 57-13-6 | Information reviewed but value not estimated. Refer to IRIS Summary. | ||||||
| 546 | Vanadium pentoxide | 1314-62-1 | Not Assessed under the IRIS program. | ||||||
| 547 | Vernam | 1929-77-7 | Not Assessed under the IRIS program. | ||||||
| 548 | Vinclozolin | 50471-44-8 | Not Assessed under the IRIS program. | ||||||
| 549 | Vinyl acetate | 108-05-4 | Nasal epithelial lesions | mg /m3 | 2x10-1 | NOAEL (HEC) | 5 | High | 0512 |
| 550 | Vinyl bromide | 593-60-2 | Hypertrophy, basophilic and eosinophilic foci, in the liver | mg /m3 | 3x10-3 | LOAEL (HEC) | 7.7 | Low | 0671 |
| 551 | Vinyl chloride | 75-01-4 | Liver cell polymorphism | mg /m3 | 1x10-1 | NOAEL (HEC) | 2.5 | Medium | 1001 |
| 552 | Warfarin | 81-81-2 | Not Assessed under the IRIS program. | ||||||
| 553 | White phosphorus | 7723-14-0 | Not Assessed under the IRIS program. | ||||||
| 554 | Xylenes | 1330-20-7 | Impaired motor coordination (decreased rotarod performance) | mg /m3 | 0.1 | NOAEL (HEC) | 39 | Medium | 0270 |
| 555 | Zinc and Compounds | 7440-66-6 | Not Assessed under the IRIS program. | ||||||
| 556 | Zinc cyanide | 557-21-1 | Not Assessed under the IRIS program. | ||||||
| 557 | Zinc phosphide | 1314-84-7 | Not Assessed under the IRIS program. | ||||||
| 558 | Zineb | 12122-67-7 | Not Assessed under the IRIS program. |
Rationale
See also
Keywords
References
Related files
<mfanonymousfilelist></mfanonymousfilelist>
